Company Filing History:
Years Active: 2008-2009
Title: Sydney Morgan Zaremba: Innovator in Cytokine Research
Introduction
Sydney Morgan Zaremba is a notable inventor based in Alameda, CA. He has made significant contributions to the field of cytokine research, particularly through his innovative patents. With a total of 2 patents, Zaremba's work focuses on developing therapeutic options for various pulmonary and immunological disorders.
Latest Patents
Zaremba's latest patents include groundbreaking inventions related to interleukin-9 and interleukin-4 chimeric antagonist muteins. The first patent provides chimeric polypeptide antagonists that include an interleukin-4 (IL-4) mutein linked to an interleukin-9 (IL-9) mutein. This invention outlines methods for using these chimeric mutein antagonists to reduce or inhibit cell responsiveness to cytokines such as IL-4, IL-9, and interleukin-13. It also details methods for treating disorders like asthma and other pulmonary conditions. The second patent focuses on IL-9 muteins that inhibit the activity of wild-type IL-9. This invention includes multimers and Fc-fusion constructs of IL-9 proteins, along with methods for purifying IL-9 proteins produced by eukaryotic cells. These muteins and their related formulations offer potential treatment options for conditions where inhibiting IL-9 mediated immune responses is beneficial.
Career Highlights
Throughout his career, Zaremba has worked with prominent companies in the pharmaceutical industry, including Aerovance, Inc. and Bayer Pharmaceuticals Corporation. His experience in these organizations has contributed to his expertise in cytokine research and therapeutic development.
Collaborations
Zaremba has collaborated with notable colleagues, including David C Boisvert and Malinda Longphre. These partnerships have likely enhanced his research and innovation efforts in the field.
Conclusion
Sydney Morgan Zaremba is a distinguished inventor whose work in cytokine research has the potential to impact the treatment of various disorders. His innovative patents reflect his commitment to advancing medical science and improving patient outcomes.